World News Insights
1-3 Minute Gist
Support LyrArc
Reader contributions keep LyrArc open for everyone
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
Direct From the Editor / On Topics Vital to the Nation
Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.
All Topics Articles
LyrArc brings in selected articles from many of the world's top publications.
Articles are selected by experts and you can see the gist of the important articles.
4
Groups
LyrArc Article Gist
New discoveries by Hamm's Continental Resources, could change the way the U.S. thinks about oil and natural gas. After years of OPEC dependence, the U.S. could become energy sufficient by 2020. His company pioneered the search for oil and natural gas in the Bakken fields in the Great Plains. The U.S. Geological Survey says Bakken has 4-5 billion barrels of oil. Hamm says the entire field, fully developed, holds 24 billion barrels.
New discoveries by Hamm's Continental Resources, could change the way the U.S. thinks about oil and natural gas. After years of OPEC dependence, the U.S. could become energy sufficient by 2020. His company pioneered the search for oil and natural gas in the Bakken fields in the Great Plains. The U.S. Geological Survey says Bakken has 4-5 billion barrels of oil. Hamm says the entire field, fully developed, holds 24 billion barrels.
1
Groups
6
Groups
LyrArc Article Gist
Britain's National Institute for Health and Clinical Excellence (NICE) says Glaxo's drug Benlysta for lupus is not "good value for money." The drug is priced at 10,000 pounds a year in the U.K. ($15,600) and much higher at $35,000 a year in the U.S. Benlysta is covered by insurers in the U.S. and some European state run health systems according to Glaxo. NICE also rejected a new multiple sclerosis drug Gilenya, which costs 19,000 pounds a year in the U.K. ($29,700), and $48,000 a year in the U.S.
Britain's National Institute for Health and Clinical Excellence (NICE) says Glaxo's drug Benlysta for lupus is not "good value for money." The drug is priced at 10,000 pounds a year in the U.K. ($15,600) and much higher at $35,000 a year in the U.S. Benlysta is covered by insurers in the U.S. and some European state run health systems according to Glaxo. NICE also rejected a new multiple sclerosis drug Gilenya, which costs 19,000 pounds a year in the U.K. ($29,700), and $48,000 a year in the U.S.
Support LyrArc
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us